ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

China flag China · Delayed Price · Currency is CNY
41.23
+0.87 (2.16%)
At close: Apr 29, 2026
Market Cap6.25B +69.7%
Revenue (ttm)458.30M +48.5%
Net Income-3.52M
EPS-0.02
Shares Out151.47M
PE Ration/a
Forward PEn/a
Dividend0.20 (0.50%)
Ex-Dividend DateJul 10, 2025
Volume8,705,912
Average Volume13,956,674
Open40.20
Previous Close40.36
Day's Range39.80 - 41.85
52-Week Range19.67 - 65.03
Beta0.02
RSI42.19
Earnings DateApr 28, 2026

About ChengDa Pharmaceuticals

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, ... [Read more]

Sector Healthcare
Founded 1980
Employees 656
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301201
Full Company Profile

Financial Performance

In 2025, ChengDa Pharmaceuticals's revenue was 406.37 million, an increase of 21.99% compared to the previous year's 333.13 million. Losses were -11.93 million, -57.56% less than in 2024.

Financial Statements